Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07803055 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease

Study acronym: GLEVAD
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This project aims to longitudinally profile plasma-derived GDEVs and plasma biomarkers of neuroinflammation across three stages of the AD continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Dementia), exploring their association with biomarkers of amyloidopathy, tauopathy and neurodegeneration, cognitive status and clinical outcome over time. Moreover, GDEVs - collected from subjects at different disease stages - will be used to treat human neurons derived from induced pluripotent stem cells (iPSCs) from healthy controls in order to assess the induced differential neurotoxic or priming effects. This dual translational approach may help identify early pathogenic signatures of neuroinflammation and elucidate their role in disease progression.
Trial Details
NCT Number NCT07803055
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions
(from sponsor)		 Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease Dementia, Alzheimer's Disease (AD)
Related terms Alzheimer Disease, Cognitive Dysfunction, Neuroinflammatory Diseases
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov